Welcome to our dedicated page for DFP Holdings SEC filings (Ticker: DFPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DFP Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DFP Holdings's regulatory disclosures and financial reporting.
Oncology Institute, Inc. (TOI) director equity grant reported
A director of Oncology Institute, Inc. reported receiving new equity awards in the form of restricted stock units (RSUs). On 11/20/2025, the reporting person acquired 46,296 shares of common stock through RSUs that will vest in full on the company’s 2026 annual stockholder meeting date, conditioned on continued service. On the same date, the director also acquired 37,037 fully vested RSUs, with no cash price per share reported for either grant. Following these transactions, the director beneficially owns 333,539 shares of TOI common stock directly.
Oncology Institute, Inc. (TOI) director equity grants reported
A reporting person who serves as a director of Oncology Institute, Inc. disclosed the receipt of two grants of common stock in the form of restricted stock units on 11/20/2025. One grant covers 47,840 restricted stock units that vest in full on the company’s 2026 annual stockholder meeting date, conditioned on continued service through that date. The second grant covers 37,037 restricted stock units that were fully vested upon grant. Both entries show a price of $0, reflecting that these are equity awards rather than open-market purchases. After these grants, the reporting person beneficially owns 288,286 shares of common stock in direct ownership.
Oncology Institute, Inc. (TOI) director Mark L. Pacala reported equity awards on a Form 4 for transactions dated 11/20/2025. He acquired 46,296 shares of common stock in the form of restricted stock units that vest in full on the company’s 2026 annual stockholder meeting date, subject to continued service. He also acquired 35,494 restricted stock units that were fully vested upon grant, both at a stated price of $0 per share. Following these transactions, he beneficially owned 256,761 shares of common stock directly.
Oncology Institute, Inc. (TOI) reported a Form 4 for director Brad Hively covering equity awards on 11/20/2025. The filing shows two grants of common stock in the form of restricted stock units at a price of $0 per share. One grant for 41,667 shares consists of restricted stock units that vest in full on the company’s 2026 annual stockholder meeting date, conditioned on continued service through that date. A second grant for 32,407 shares consists of restricted stock units that were fully vested upon grant. Following these transactions, Hively beneficially owns 697,054 shares of common stock directly.
Oncology Institute, Inc. (TOI) director Mark L. Pacala reported multiple open-market sales of company common stock. On 11/18/2025, he sold 2,160, 1,210, and 46,630 shares of TOI common stock, each at a price of $4 per share, according to the Form 4.
After these transactions, Pacala directly beneficially owned 174,971 shares of TOI common stock. The filing notes that the sales represent shares acquired from previously vested restricted stock unit (RSU) awards.
Oncology Institute, Inc. (TOI) reported an insider ownership change by a director. On 11/18/2025, the reporting person acquired 141,149 shares of common stock in a transaction coded "J". After this transaction, the director beneficially owned 250,206 shares, held directly.
According to the explanation, these shares were received through an in-kind distribution from M33 Growth I, L.P. to its limited partners on a pro rata basis, in accordance with their pecuniary interests, relying on Rules 16a-9 and 16a-13 under the Securities Exchange Act of 1934.
Oncology Institute, Inc. (TOI) reported changes in ownership by an affiliated investment group on a joint Form 4. The reporting persons, including entities related to M33 Growth, are identified as directors of the company.
On November 18, 2025, TOI M, LLC made an in-kind distribution of 590,892 shares of TOI common stock to its members, including 11,818 shares to M33 Growth I L.P. ("M33 LP"). Also on that date, M33 LP made an in-kind distribution of 2,500,000 shares of TOI common stock to its limited partners. After these transactions, one line in the table shows 7,944,207 shares and another shows 5,444,207 shares beneficially owned, both marked as directly held.
The transactions are coded as "J" (other) and reflect reallocations of shares among affiliated funds rather than open-market purchases or sales.
Oncology Institute, Inc. (TOI) shareholder M33 Growth I LP filed Amendment No. 5 to its Schedule 13D to update its ownership in the company’s common stock.
The reporting persons now beneficially own 6,802,656 shares of TOI common stock, including 5,444,207 shares held by M33 Growth I LP and 1,358,449 shares issuable upon exercise of warrants with a $1.1980 per share exercise price. This represents 5.46% of TOI’s common stock, based on 98,381,340 shares outstanding as of November 6, 2025 plus the warrant shares.
On November 18, 2025, M33 Growth I LP distributed 2,488,182 shares of common stock in-kind to its limited partners, and TOI M, LLC distributed 590,892 shares in-kind to its members. Following these distributions, TOI M, LLC no longer beneficially owns any TOI common stock, while M33 Growth I LP and its general partner M33 Growth I GP LLC continue to report shared voting and dispositive power over 6,802,656 shares.
Oncology Institute, Inc. (TOI) shareholder M33 Growth I LP filed Amendment No. 5 to its Schedule 13D to update its ownership in the company’s common stock.
The reporting persons now beneficially own 6,802,656 shares of TOI common stock, including 5,444,207 shares held by M33 Growth I LP and 1,358,449 shares issuable upon exercise of warrants with a $1.1980 per share exercise price. This represents 5.46% of TOI’s common stock, based on 98,381,340 shares outstanding as of November 6, 2025 plus the warrant shares.
On November 18, 2025, M33 Growth I LP distributed 2,488,182 shares of common stock in-kind to its limited partners, and TOI M, LLC distributed 590,892 shares in-kind to its members. Following these distributions, TOI M, LLC no longer beneficially owns any TOI common stock, while M33 Growth I LP and its general partner M33 Growth I GP LLC continue to report shared voting and dispositive power over 6,802,656 shares.
The Oncology Institute, Inc. (TOI) reported that its Chief Executive Officer acquired additional common stock through a stock-based award. On 11/17/2025, the officer received 6,464 shares of common stock at a stated price of $0.00 per share, increasing their directly held stake to 1,799,984 shares.
The filing explains that these 6,464 shares represent restricted stock units (RSUs) that were fully vested upon grant, after shares were withheld to cover tax obligations. This is a routine equity compensation event that aligns the CEO’s interests more closely with those of other shareholders.
Oncology Institute, Inc. (TOI) reported an insider equity transaction by a person serving as Chief Medical Officer on a Form 4. On 11/17/2025, this reporting person acquired 2,086 shares of common stock at $0.00 per share. These shares represent restricted stock units that were fully vested upon grant and delivered net of withholding tax obligations.
After this transaction, the reporting person directly beneficially owns 237,930 shares of Oncology Institute common stock.